Clinical trial · Observational
Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
NCT04407143CI-TRIAL-00102761SOLIDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Corona Virus Infection | — | UNRESOLVED | — |
| COVID | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IgG test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- lung cancer+COVID-19
- description
- Lung cancer patients infected by COVID-19
- interventionNames
- Diagnostic Test: IgG test
Primary outcomes (1)
- measure
- Description of the characteristics of patients
- timeFrame
- From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks
- description
- Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.
Secondary outcomes (1)
- measure
- Detection of antibodies (IgG) at 6 months after SARS-COV2 vaccines
- timeFrame
- From the date of complete SARS-COV2 vaccination administration until 6 month
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients diagnosed with lung cancer at any stage of the disease 2. Age ≥ 18 3. Patients who have signed the informed consent for this study Exclusion Criteria: 1\. Patients who have not signed or do not wish to sign the informed consent for this study
References
Publications (2)
- DERIVEDProvencio M, Estival A, Franco F, Lopez-Vivanco G, Saigi M, Arasanz H, Diz P, Carcereny E, Garcia J, Aguado C, Mosquera J, Iruarrizaga E, Majem M, Bosch-Barrera J, Mielgo-Rubio X, Guirado M, Juan-Vidal O, Blasco A, Lucia Gozalvez C, Del Barrio A, De Portugal T, Lopez-Martin A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Marti-Ciriquian JL, Del Barco E, Calvo V; Spanish Lung Cancer Group (SLGC/GECP). Immunogenicity of COVID-19 vaccines in lung cancer patients. Lung Cancer. 2023 Oct;184:107323. doi: 10.1016/j.lungcan.2023.107323. Epub 2023 Aug 9. PMID 37639820
- DERIVEDProvencio M, Rodriguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, Lopez Vivanco G, Guirado M, Benitez G, Estival A, Calvo V, Jimenez B, Arasanz H, Coves J, Majem M, Massuti B, Vazquez S, Juan-Vidal O, Collazo-Lorduy A, Gozalvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, Lopez-Martin A, Cordoba JF, de Asis Aparisi F, Zafra M, Mosquera J, Perez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martin P, Cuesta de Juan S, Cobo M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. doi: 10.21037/tlcr-21-504. PMID 35242627